相似文献
1
In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.
Antimicrob Agents Chemother. 2003 Jul;47(7):2362-5. doi: 10.1128/AAC.47.7.2362-2365.2003.
2
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
3
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Mol Cell Probes. 2010 Jun;24(3):154-60. doi: 10.1016/j.mcp.2010.01.003. Epub 2010 Jan 25.
4
Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Antimicrob Agents Chemother. 2001 Mar;45(3):734-8. doi: 10.1128/AAC.45.3.734-738.2001.
5
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
J Urol. 2000 Sep;164(3 Pt 1):847-51. doi: 10.1097/00005392-200009010-00060.
6
In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6. doi: 10.1128/AAC.44.10.2740-2746.2000.
7
In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
Vet Microbiol. 2014 Dec 5;174(3-4):514-522. doi: 10.1016/j.vetmic.2014.10.011. Epub 2014 Oct 25.
8
Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae.
APMIS. 2002 Sep;110(9):651-7. doi: 10.1034/j.1600-0463.2002.1100909.x.
9
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74. doi: 10.1128/AAC.40.8.1768.
10
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
J Antimicrob Chemother. 2001 Sep;48(3):365-74. doi: 10.1093/jac/48.3.365.
引用本文的文献
1
Preliminary insights into the potential role of Acanthamoeba-Pseudomonas interactions in the development of antibiotic resistance.
Access Microbiol. 2025 Jun 30;7(6). doi: 10.1099/acmi.0.000999.v3. eCollection 2025.
2
Synthesis of Novel Thiazole/Thiadiazole Conjugates of Fluoroquinolones as Potent Antibacterial and Antimycobacterial Agents.
Chem Biol Drug Des. 2025 May;105(5):e70126. doi: 10.1111/cbdd.70126.
3
Development of Effective Medical Countermeasures Against the Main Biowarfare Agents: The Importance of Antibodies.
Microorganisms. 2024 Dec 18;12(12):2622. doi: 10.3390/microorganisms12122622.
4
Prediction of Human Microbe-Drug Association based on Layer Attention Graph Convolutional Network.
Curr Med Chem. 2024;31(31):5097-5109. doi: 10.2174/0109298673249941231108091326.
5
Genetic basis of clarithromycin resistance in .
Microbiol Spectr. 2024 Jun 4;12(6):e0418023. doi: 10.1128/spectrum.04180-23. Epub 2024 Apr 26.
6
8-OxoG-Dependent Regulation of Global Protein Responses Leads to Mutagenesis and Stress Survival in .
Antioxidants (Basel). 2024 Mar 8;13(3):332. doi: 10.3390/antiox13030332.
7
Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0149723. doi: 10.1128/aac.01497-23. Epub 2024 Feb 15.
8
DNA Gyrase as a Target for Quinolones.
Biomedicines. 2023 Jan 27;11(2):371. doi: 10.3390/biomedicines11020371.
9
Quinolone Antibiotics: Resistance and Therapy.
Infect Drug Resist. 2023 Feb 10;16:811-820. doi: 10.2147/IDR.S401663. eCollection 2023.
10
Role of the Water-Metal Ion Bridge in Quinolone Interactions with Gyrase.
Int J Mol Sci. 2023 Feb 2;24(3):2879. doi: 10.3390/ijms24032879.
本文引用的文献
1
Mutations of Bacteria from Virus Sensitivity to Virus Resistance.
Genetics. 1943 Nov;28(6):491-511. doi: 10.1093/genetics/28.6.491.
2
Antimicrobial susceptibilities of diverse Bacillus anthracis isolates.
Antimicrob Agents Chemother. 2002 Dec;46(12):3843-5. doi: 10.1128/AAC.46.12.3843-3845.2002.
3
The prophylaxis and treatment of anthrax.
Int J Antimicrob Agents. 2002 Nov;20(5):320-5. doi: 10.1016/s0924-8579(02)00200-5.
4
Bacillus anthracis and antibacterial agents.
Clin Microbiol Infect. 2002 Aug;8(8):467-78. doi: 10.1046/j.1469-0691.2002.00527.x.
5
Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.
Antimicrob Agents Chemother. 2002 Jul;46(7):2307-9. doi: 10.1128/AAC.46.7.2307-2309.2002.
6
Molecular analysis of rifampin resistance in Bacillus anthracis and Bacillus cereus.
Antimicrob Agents Chemother. 2002 Feb;46(2):511-3. doi: 10.1128/AAC.46.2.511-513.2002.
7
In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.
Int J Antimicrob Agents. 2001 Dec;18(6):559-62. doi: 10.1016/s0924-8579(01)00464-2.
8
Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Dec;45(12):3517-23. doi: 10.1128/AAC.45.12.3517-3523.2001.
9
Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis.
J Bacteriol. 2000 May;182(10):2928-36. doi: 10.1128/JB.182.10.2928-2936.2000.
10
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
Antimicrob Agents Chemother. 2000 Feb;44(2):462-6. doi: 10.1128/AAC.44.2.462-466.2000.
Zotero 插件